While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026. | While the threat of U.S. import tariffs ...
Biosimilar execs optimistic on the state of US biosims as Sandoz locks in on ‘golden decade’ to come
As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...
As Samsung Biologics’ contract manufacturing business continues to fire on all cylinders, the CDMO has earned a unique ...
After U.S. President Donald Trump took the stage at the World Economic Forum this week to tout the supposed success of his ...
Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that it’s not ...
As Lindsey Vonn’s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the ...
With $30 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI), Merck & Co. | The project, which involves Merck, SK Biosciences, Hilleman Laboratories and CDMO IDT ...
Hours before Johnson & Johnson revealed strong financial results for 2025 and rosy expect | In Johnson & Johnson's ...
In 2022, Pfizer became the first biopharma company to generate annual revenue of $100 billion. | Led by cancer standout ...
As the U.S. government intensifies efforts to acquire Greenland, President Donald Trump has responded to European pushback ...
As IntraBio works to grow the global treatment market for Aqneursa in Niemann-Pick disease type C, the company is already ...
Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback